Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals

Rapid Communications in Mass Spectrometry

Volumn 24, Issue 10, 2010, Pages 1481-1489

  Salehpour, Mehran ^a,b   Ekblom, Jonas ^c   Sabetsky, Vladimir ^c   Håkansson, Karl ^a   Possnert, Göran ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Zeptologix Biosciences AB   (Sweden)

^c Bows Pharmaceuticals AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DRUG PRODUCTS; MASS SPECTROMETRY; PARTICLE ACCELERATORS;

ACCELERATOR MASS SPECTROMETRY; ANALYTICAL METHOD; CASE-STUDIES; DRUG DEVELOPMENT; MICRODOSING; PHARMACEUTICAL DRUGS; PROTEIN PHARMACEUTICALS; SAMPLE SIZES; STRATEGIC TOOL; ULTRASENSITIVE;

PROTEINS;

EID: 77951918031     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.4544     Document Type: Article

References (39)

1. Tuniz C, Bird JR, Fink D, Herzog GF. Accelerator Mass Spectrometry, Ultrasensitive Analysis for Global Science. CRC Press: Boca Raton, 1998.
2. Elmore D, Philips FM. Science 1987; 236: 543.
3. Vogel JS, Turteltaub JW. Nucleic Instrum. Methods B 1994; 92: 445.
4. Vogel JS, Turtetaub JW, Finkel R, Nelson DE. Anal. Chem. 1995; 67: A353.
5. Lappin G, Garner RC. Nat. Rev. Drug Discovery 2003; 2: 233.
6. Food and Drug Administration, US Department of Health and Human Services. Guidelines for Industry Investigators and Reviewers: Exploratory IND Studies. FDA: Rockville, MD, 2006.
7. Position Paper on Non-clinical Safety Studies to Support Clinical Trials with a Single Microdose, Position Paper CPMP/SWP/ 2599, EMEA: London, 2004.
8. Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, CPMP/ICH/286/95, EMEA: London, 2009.
9. Wagner CC, Bauer M, Simpson M, Lappin G, Karch R, Feurstein T, Kletter K, Muller M, Zeitlinger M, Langer O. Presented at 9th Congress of the European Association of Clinical Pharmacology and Therapeutics. Abstract in: Basic and Clinical Pharmacology & Toxicology 105 Supplement 1: 23_oral. 2009: Edinburgh, UK
10. Lappin G, Wagner CC, Langer O, Van der Merb N. Bio Analysis 2009; 1: 357.
11. Salehpour M, Forsgard N, Possnert G. Rapid Commun. Mass Spectrom. 2009; 23: 557.
12. Lappin G, Garner RC, Meyers T, Powel J, Varley P. J. Pharm. Biomed. Anal. 2006; 41: 1299.
13. Aronson J, Ferner R. Br. Med. J. 2003; 327: 1222.
14. Bogdanovic S, Langlands B. Next Generation Protein Engineering & Drug Design. Datamonitor Inc. Business Insights Ltd., 2007.
15. Kang JS, Deluca PP, Lee KC. Expert Opin. Emerg. Drugs 2009; 14: 363.
16. von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Exp. Clin. Endocrinol. Diabetes 2002; 110: 416.
17. Mahato RI, Narang AS, Thoma L, Miller DD. Crit. Rev. Ther Drug. 2003; 20: 153.
18. Delie F, Blanco-Príeto M-J. Molecules 2002; 10: 65.
19. Peppas NA. Int. J. Pharmaceutics 2004; 277: 11.
20. The Food and Drug Administration (FDA). Guidance for Industry: Investigators and Reviewers, Exploratory IND Studies, January 2006.
21. Sabetsky V, Ekblom J. Pharmacol. Res. 2010; 61: 1.
22. Binder C, Lauritzen T, Faber O, Pramming S. Diabetes Care 1984; 7: 188.
23. Bernkop-Schnurch A, Clausen AE, Guggi D. Med. Chem. Rev. 2004; 1: 1.
24. The Food and Drug Administration. Guidance for Industry and Researchers. The Radioactive Drug Research Committee: Human Research Without an Investigational New Drug Application. FDA: Rockville, 2009.
25. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Drug Safety 2009; 32: 811.
26. Salehpour M, Possnert G, Bryhni H. Anal. Chem. 2008; 80: 3515.
27. Salehpour M, Forsgard N, Possnert G. Rapid Commun. Mass Spectrom. 2008; 22: 3928.
28. Vogel JS, Turtetaub JW. Adv. Exp. Med. Biol. 1998; 445: 397.
29. Ognibene TJ, Bench G, Vogel JS. Anal. Chem. 2003; 75: 2192.
30. Bhardwaj RD, Curtis MA, Spalding KS, Buchholz BA, Fink D, Bjork-Eriksson T, Nordborg C, Gage FG, Druis H, Eriksson PS, FrisénJ.Proc. Nat. Acad. Sci.2006;103:12564.
31. Bergman O, Bhardwaj RD, Bernard S, Zdunek S, Barnebé-Heider F, Walsh S, Zupicich J, Alkass K, Buchholtz BA, Druid H, Jovinge S, Frisen J. Science 2009; 324: 98.
32. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Naslund E, Britton T, Concha H, Hassan M, Rydén M, Frisén J, Arner P. Nature 2008; 453: 783.
33. Available: http://www.thrm.ki.se.
34. Santos GM, Southon JR, Friffin S, Beaupre SR, Druffel ERM. Nucleic Instrum. Methods B 2007; 259: 293.
35. Khosh MS, Xu X, Trumbore SE. Proc. 11th Int. Conf. Accelerator Mass Spectrometry, September 14-19, 2008, Rome, Italy. Nucleic Instrum. Methods B; in press.
36. Kim S-H, Kelly PB, Clifford AJ. Anal. Chem. 2009; 81: 5949.
37. Hua Q, Zoppi U, Williams AA, Smith AM. Nucleic Instrum. Methods B 2004; 223: 284.
38. Salehpour M, Possnert G, Bryhni H, Palminger-Hallén I, Stahle L. Appl. Radiat. Isot. 2009; 67: 495.
39. Forsgard N, Salehpour M, Possnert G. J. Anal. At. Spectrom. 2010; 25: 74.